07:00 , Apr 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Epoxide hydrolase 2 (EPHX2; CEH) Cell culture and mouse studies suggest a combination of fish oil-derived epoxy docosapentaenoic acids (EDPs) and EPHX2 inhibitors could...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Galleon management update

Galleon Pharmaceuticals Inc. , Newtown, Pa.   Business: Infectious, Pulmonary   Hired: D. Euan MacIntyre as SVP of drug discovery, formerly a SVP and head of drug discovery at Arete Therapeutics Inc. ; and James...
07:00 , Sep 24, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular; inflammation Epoxide hydrolase 2 (EPHX2) In vitro studies identified benzamide-based compounds that could help treat cardiovascular disease. High-throughout screening identified N-(3,3-diphenyl-propyl)-nicotinamide as having...
08:00 , Feb 23, 2009 |  BioCentury  |  Product Development

A more excellent choice

Arete Therapeutics Inc. decided to switch gears and focus on developing its first-in-class oral soluble epoxide hydrolase inhibitor for Type II diabetes rather than hypertension based on a more robust antidiabetic profile in preclinical models....
08:00 , Feb 16, 2009 |  BC Week In Review  |  Clinical News

AR9281: Phase IIa started

Arete began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate oral AR9281 in 150 treatment-naïve, pre-diabetic patients. Arete Therapeutics Inc. , Hayward, Calif.   Product: AR9281   Business: Endocrine   Molecular target: Epoxide hydrolase...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

AR9281: Phase Ib data

Top-line data from a 7-day, double-blind, placebo-controlled, U.S. Phase Ib trial in 24 healthy volunteers showed that up to 1,200 mg/day of oral AR9281 was well tolerated with no observed dose-related adverse events. Arete Therapeutics...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Company News

Arete management update

Arete Therapeutics Inc. Hayward, Calif.   Business: Cardiovascular, Inflammation   Hired: James Sabry, chairman and former CEO of Cytokinetics Inc. , as president and CEO; he replaces Dinesh Patel  ...
00:59 , Jul 9, 2008 |  BC Extra  |  Company News

Arete names Sabry CEO

Cardiovascular, inflammation and metabolic company Arete (Hayward, Calif.) hired James Sabry as president and CEO. The chairman and former CEO of Cytokinetics (NASDAQ:CYTK) has been a strategic advisor to Arete and a member of the...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Arete board of directors update

Arete Therapeutics Inc. , Hayward, Calif.   Business: Cardiovascular, Inflammation   Appointed: Donald Santel, formerly CEO of Actelion Ltd. 's CoTherix Inc. subsidiary  ...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

AR9281: Phase I started

Arete began the placebo-controlled, U.S. Phase I trial of oral AR9281 in up to 32 healthy volunteers. Arete Therapeutics Inc. , Hayward, Calif.   Product: AR9281   Business: Cardiovascular   Molecular target: NA   Description:...